Gilead Sciences, Inc.
The Details: Gilead Sciences reported quarterly earnings of $1.81 per share, which beat the analyst consensus estimate of $1.76. Quarterly revenue came in at $6.67 billion, which missed the analyst consensus estimate of $6.77 billion and is a decrease from revenue of $6.69 billion year-over-year.
For the first quarter, the company reported:
- HIV product sales increased 6% to $4.6 billion in the first quarter of 2025 compared to the same period in 2024, primarily driven by higher average realized price and demand.
- Liver Disease portfolio sales increased 3% to $758 million in the first quarter of 2025 compared to the same period in 2024. This was primarily driven by increased demand in products for primary biliary cholangitis, chronic hepatitis B virus and chronic hepatitis delta virus, partially offset by lower average realized price for chronic hepatitis C virus products.
- Veklury sales decreased 45% to $302 million in the first quarter of 2025 compared to the same period in 2024, primarily driven by lower rates of COVID-19-related hospitalizations across regions.
- Cell Therapy product sales decreased 3% to $464 million in the first quarter 2025 compared to the same period in 2024.
“Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said Daniel O’Day, Gilead’s CEO.
“Our base business grew 4% year-over-year, primarily led by Biktarvy’s continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer,” O’Day added.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.